CLINICAL TRIALS PROFILE FOR PEGINTERFERON ALFA-2B

All Clinical Trials for peginterferon alfa-2b

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001854 ↗	Long-Term Therapy With Ribavirin for Chronic Hepatitis C	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 4	1999-02-12	Chronic hepatitis C is a disease of the liver caused by the hepatitis C virus. The disease can be serious and even fatal. Approximately 25% of patients with chronic hepatitis C will develop cirrhosis and some of these patients will develop cancer of the liver or liver failure. Presently the disease is treated with a combination of alpha interferon or peginterferon (antiviral and immune stimulating drugs) and ribavirin (an antiviral drug). Alpha interferon is given by injection three times a week whereas peginterferon is given by injection only once a week. Ribavirin is given as a tablet by mouth twice a day. The combination therapy is given for 6 to months. About half of the patients given these medications will receive a lasting benefit and many patients do not respond well to the combination therapy. This study will select up to 50 patients will chronic hepatitis C who have not responded to combination therapy or who could not stand the side effects associated with interferon or peginterferon therapy. These subjects will be evaluated and undergo liver biopsy to determine their present liver condition. If selected as subjects they will be started on single drug therapy with ribavirin. The drug will be given orally twice a day at a dose based on the patient's body weight. The patients will be followed on an out-patient basis. They will we asked to return for regular check-ups and blood tests every 2 to 8 weeks for the duration of the study. After 6 months, the medication will be stopped or adjusted based on the results of the subject's blood tests (liver enzymes). A response is considered if a decrease of 50% or more of the initial liver enzyme (alanine aminotransferase, ALT) is noted. A complete response will be considered if liver enzymes return to normal levels. Therapy will be discontinued after 6 months if patients do not respond. However, patients that respond to the single drug therapy will continue to receive the medication at a decreased dose. The patients will remain on an appropriate dose for up to 8 years with repeat liver biopsies at 2, 4 and 8 years to assess progress. This study will determine if long-term therapy with ribavirin is safe and effective.
NCT00006164 ↗	Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment	Completed	Hoffmann-La Roche	Phase 3	2000-06-01	The HALT-C Trial is a National Institute of Diabetes and Digestive and Kidney Diseases sponsored, randomized clinical trial of long-term use of Peginterferon alfa-2a (pegylated interferon) in patients who failed to respond to prior interferon treatment. All patients who enter the trial will be treated for 6 months with Peginterferon alfa-2a and Ribavirin. Patients who respond to this 6 month treatment will continue to be treated for an additional 6 months. Patients who do not respond to this treatment will be eligible for the long-term maintenance phase of this study where patients will be randomly selected to be treated with Peginterferon alfa-2a or to discontinue treatment for 3.5 years. Patients in both arms of this study will be followed closely with quarterly study visits. The combination of peginterferon plus ribavirin has recently been approved by the FDA for treatment of chronic hepatitis C. Patients who remain HCV-RNA positive after being treated for at least 6 months with peginterferon and ribavirin outside of this study may be eligible to directly enter the randomized portion of the HALT-C Trial. The HALT-C study is designed to determine if continuing interferon long-term over several years will suppress Hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer and reduce the need for liver transplantation.
NCT00006164 ↗	Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment	Completed	National Cancer Institute (NCI)	Phase 3	2000-06-01	The HALT-C Trial is a National Institute of Diabetes and Digestive and Kidney Diseases sponsored, randomized clinical trial of long-term use of Peginterferon alfa-2a (pegylated interferon) in patients who failed to respond to prior interferon treatment. All patients who enter the trial will be treated for 6 months with Peginterferon alfa-2a and Ribavirin. Patients who respond to this 6 month treatment will continue to be treated for an additional 6 months. Patients who do not respond to this treatment will be eligible for the long-term maintenance phase of this study where patients will be randomly selected to be treated with Peginterferon alfa-2a or to discontinue treatment for 3.5 years. Patients in both arms of this study will be followed closely with quarterly study visits. The combination of peginterferon plus ribavirin has recently been approved by the FDA for treatment of chronic hepatitis C. Patients who remain HCV-RNA positive after being treated for at least 6 months with peginterferon and ribavirin outside of this study may be eligible to directly enter the randomized portion of the HALT-C Trial. The HALT-C study is designed to determine if continuing interferon long-term over several years will suppress Hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer and reduce the need for liver transplantation.
NCT00006164 ↗	Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	2000-06-01	The HALT-C Trial is a National Institute of Diabetes and Digestive and Kidney Diseases sponsored, randomized clinical trial of long-term use of Peginterferon alfa-2a (pegylated interferon) in patients who failed to respond to prior interferon treatment. All patients who enter the trial will be treated for 6 months with Peginterferon alfa-2a and Ribavirin. Patients who respond to this 6 month treatment will continue to be treated for an additional 6 months. Patients who do not respond to this treatment will be eligible for the long-term maintenance phase of this study where patients will be randomly selected to be treated with Peginterferon alfa-2a or to discontinue treatment for 3.5 years. Patients in both arms of this study will be followed closely with quarterly study visits. The combination of peginterferon plus ribavirin has recently been approved by the FDA for treatment of chronic hepatitis C. Patients who remain HCV-RNA positive after being treated for at least 6 months with peginterferon and ribavirin outside of this study may be eligible to directly enter the randomized portion of the HALT-C Trial. The HALT-C study is designed to determine if continuing interferon long-term over several years will suppress Hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer and reduce the need for liver transplantation.

Clinical Trial Conditions for peginterferon alfa-2b

Condition Name

Condition Name for peginterferon alfa-2b
Intervention	Trials
Hepatitis C, Chronic	126
Hepatitis C	104
Chronic Hepatitis C	85
Chronic Hepatitis B	38

Condition MeSH

Condition MeSH for peginterferon alfa-2b
Intervention	Trials
Hepatitis	414
Hepatitis A	379
Hepatitis C	345
Hepatitis, Chronic	270

Clinical Trial Locations for peginterferon alfa-2b

Trials by Country

Trials by Country for peginterferon alfa-2b
Location	Trials
Canada	209
Italy	131
China	125
Germany	118
Australia	118

Trials by US State

Trials by US State for peginterferon alfa-2b
Location	Trials
California	110
Texas	100
New York	91
Florida	83
Maryland	83

Clinical Trial Progress for peginterferon alfa-2b

Clinical Trial Phase

Clinical Trial Phase for peginterferon alfa-2b
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	1

Clinical Trial Status

Clinical Trial Status for peginterferon alfa-2b
Clinical Trial Phase	Trials
Completed	340
Terminated	48
Unknown status	47

Clinical Trial Sponsors for peginterferon alfa-2b

Sponsor Name

Sponsor Name for peginterferon alfa-2b
Sponsor	Trials
Hoffmann-La Roche	103
Merck Sharp & Dohme Corp.	52
Vertex Pharmaceuticals Incorporated	23

Sponsor Type

Sponsor Type for peginterferon alfa-2b
Sponsor	Trials
Other	380
Industry	367
NIH	37

Peginterferon Alfa-2b: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 30, 2026

What is peginterferon alfa-2b and what indications anchor its market?

Peginterferon alfa-2b is a pegylated interferon alfa product used in chronic viral hepatitis and, historically, oncology combinations. Commercially, the core revenue base is tied to chronic hepatitis B and chronic hepatitis C treatment pathways where peginterferon alfa regimens were standard before widespread substitution by direct-acting antivirals (DAAs).

Current anchor indications (commercial relevance)

• Chronic hepatitis C (HCV): Peginterferon alfa-2b has historically been used in combination regimens (typically with ribavirin and/or later DAA-era combinations depending on period). The HCV market has materially shifted toward DAAs, which reduced peginterferon volume growth and sustained pricing power.
• Chronic hepatitis B (HBV): Peginterferon alfa regimens retain a defined role in selected patients (e.g., finite-duration therapy pathways historically valued versus long-term nucleos(t)ide analog therapy).

Product identity

Peginterferon alfa-2b is marketed under multiple branded forms; clinical and regulatory references frequently map to Pegintron for peginterferon alfa-2b (interferon alfa-2b pegylated). (Regulatory and clinical context are based on standard references to peginterferon alfa-2b/pegintron labeling and published trial programs.) [1]

---

What is the clinical trials update for peginterferon alfa-2b?

A full, current-trial landscape requires real-time registry extraction. This response therefore covers only documented, published clinical positions and the industry-wide clinical status of peginterferon alfa-2b: a declining role in HCV due to DAAs and a persistent but constrained role in HBV where fixed-duration interferon strategies remain clinically relevant.

Clinical development direction by indication

HCV: program contraction after DAA dominance

• Peginterferon alfa-2b has faced structural demand erosion in HCV as DAAs displaced interferon-based regimens across most approved geographies.
• Remaining clinical activity focuses on comparative strategy, special populations, and mechanistic sub-studies, rather than large phase 3 registrations comparable to pre-DAA eras.

Implication for pipeline visibility: HCV trials involving peginterferon alfa-2b have not regained the scale of earlier development eras, so the observable “active pipeline” footprint is smaller and more niche than for DAAs. (This aligns with the broader HCV market trajectory and the treatment standard shift described in major consensus and commercial reviews of the interferon-to-DAA transition.) [2]

HBV: limited, strategy-focused use

• Peginterferon alfa-2b has continued to be studied for patient selection, response durability, and predictors of response.
• HBV development is less dominated by one-way substitution because therapy patterns include both finite-duration interferon approaches and long-term nucleos(t)ide analog therapy.

Implication for pipeline: clinical programs remain tied to improving response rates and response durability in subpopulations where interferon is clinically chosen.

Evidence base for efficacy endpoints that still shape trial design

Peginterferon alfa-2b trial frameworks in HBV commonly measure:

• HBsAg loss/seroclearance and durable off-therapy responses
• HBV DNA suppression
• ALT normalization and virologic response durability

For HCV, prior pivotal endpoints used:

• SVR (sustained virologic response) at 12 or 24 weeks post-treatment, which later became a benchmark that DAAs rapidly outperformed in tolerability and simplicity.

(Clinical endpoints and trial logic are anchored to standard interferon and peginterferon efficacy frameworks used across pivotal eras and in guideline-backed treatment pathways.) [1][2]

---

How big is the peginterferon alfa-2b market and where does growth come from?

Demand drivers

Peginterferon alfa-2b demand is driven by:

• HBV treated population where clinicians select interferon-based finite regimens
• Residual HCV use in settings with restricted DAA access, payer limits, or where older protocols persist
• Country-level reimbursement and guideline adoption timing
• Safety-driven regimen discontinuation compared with oral DAA or better-tolerated options

Market constraint: HCV substitution

The market headwind is the long-run shift from interferon regimens to DAAs:

• DAAs improved cure rates and reduced treatment duration and toxicity.
• The market for peginterferon in HCV therefore transitioned from primary standard-of-care to niche or legacy use.

This structural decline is reflected in multiple market analyses and guideline transitions describing the interferon-to-DAA replacement. [2]

Where peginterferon can still grow

Growth does not come from HCV re-acceleration; it comes from:

• HBV finite-duration treatment uptake
• Improved patient selection that increases on-treatment response rates and improves payer willingness to reimburse
• Tiered reimbursement structures in markets where interferon remains in formularies

---

What pricing and access dynamics determine revenue durability?

Pricing power is capped by substitution alternatives

Peginterferon alfa-2b faces pricing pressure because:

• Oral alternatives in HCV dominate in most markets.
• HBV alternatives include nucleos(t)ide analogs (long-term) and newer agent options; interferon is often evaluated on finite-duration value and response depth.

Access is constrained by tolerability and administration burden

Interferon requires:

• Injectable dosing schedules
• Monitoring for interferon-associated adverse events

This creates reimbursement friction that favors products with:

• Cleaner discontinuation rates
• Simpler administration
• Lower monitoring intensity

These constraints have been well documented in the evolution of treatment standards and physician adoption patterns as DAAs entered. [2]

---

How should investors model peginterferon alfa-2b revenue under base, bull, and bear cases?

Because this response cannot pull live trial and registry feeds or current prescription volume, the projection below is built on structural market reality: peginterferon alfa-2b demand is anchored in HBV and residual HCV, with secular decline in HCV.

Revenue model architecture (market mechanics)

• Segment 1: HBV (more durable)
• Segment 2: HCV (declining due to DAAs)
• Mix shift over time toward HBV as HCV use erodes

Base case (most likely)

• HBV remains the key support line.
• HCV contribution continues to shrink as access to DAAs expands and prescribing pathways standardize.

Bear case

• Faster guideline lock-in toward oral therapies in mixed systems
• Tighter payer controls on interferon reimbursement
• Additional safety or handling burdens reduce formulary placement

Bull case

• HBV finite-duration uptake improves through better response prediction
• Payer adoption of interferon where it delivers off-therapy response depth
• Continued availability in markets that delay DAA full substitution

Projection timeline logic

Peginterferon alfa-2b’s market trajectory follows a long tail:

• Large contraction in HCV after DAA adoption
• Slower drift in HBV driven by patient selection and reimbursement

This general pattern is consistent with the interferon-to-DAA shift described in major guideline summaries and market overviews. [2]

---

What are the key competitive substitutes and how do they impact peginterferon alfa-2b?

HCV competitive set (dominant)

• Direct-acting antivirals (DAAs) have been the primary replacement category in modern care, displacing peginterferon-based regimens.

The global standard-of-care transition is captured across major consensus and guideline discussions that chronicle the rise of DAAs and the resulting decline in interferon-based therapy. [2]

HBV competitive set (partial substitution)

• Nucleos(t)ide analogs provide continuous suppression, often preferred for broader patient segments.
• Interferon remains a finite-duration option where deeper immune-mediated outcomes are desirable and tolerability is acceptable.

Peginterferon’s HBV role persists but does not expand to replace oral continuous therapy for all patients, which caps total addressable market.

---

What regulatory and safety profile elements still affect adoption?

Peginterferon alfa-2b’s label-based clinical use includes:

• Requirement for monitoring typical of interferon therapies
• Risk management for interferon-associated adverse effects

Label constraints shape payer and clinician comfort, especially where oral regimens are available. Core labeling and historical prescribing information for peginterferon alfa-2b/pegintron inform this risk profile. [1]

---

Key Takeaways

• Peginterferon alfa-2b market demand is structurally anchored in HBV and is secularly pressured in HCV by DAAs. [2]
• Clinical activity is best characterized as niche and strategy-focused, with less probability of large HCV resurgence because oral DAAs dominate standard-of-care economics and outcomes. [2]
• Revenue durability depends on HBV finite-duration uptake, reimbursement stability, and patient selection; projection scenarios must model mix shift toward HBV and continued HCV erosion.
• Competitive displacement is not cyclical; it is driven by care pathway lock-in that shifts prescriptions toward DAAs in HCV and toward oral HBV management strategies for many patients. [2]

---

FAQs

1. Is peginterferon alfa-2b still used for HCV?
   Yes, but primarily in residual or constrained settings; DAAs have displaced interferon-based regimens as the dominant care pathway. [2]

2. What makes peginterferon alfa-2b relevant in HBV?
   It supports a finite-duration therapeutic strategy in selected patients where deeper response outcomes are targeted, unlike continuous oral suppression for many HBV patients. [2]

3. What is the biggest market risk for peginterferon alfa-2b?
   Continued expansion of DAA access and payer pathway tightening that further reduces interferon-based HCV prescribing. [2]

4. What drives adoption beyond efficacy?
   Administration burden and tolerability, including monitoring requirements typical for interferon therapies, shape formulary placement and continuation rates. [1]

5. How should a projection treat future growth?
   Model growth as HBV-supported with an HCV decline overlay, reflecting mix shift dynamics after DAAs became standard. [2]

---

References

[1] European Medicines Agency. (n.d.). Pegintron (peginterferon alfa-2b) product information and public assessment information. EMA.
[2] World Health Organization. (n.d.). Guidelines on the treatment of hepatitis C and the shift toward direct-acting antivirals. WHO.